About Xpress Biologics
Xpress Biologics is a Healthcare company based in Liege (Belgium) founded in 2014, and was acquired by Polyplus Transfection in December 2022. CRO offering recombinant protein and antibody related services for preclinical and clinical applications. The company has 51 employees. Xpress Biologics offers products and services including Recombinant Protein Manufacturing, Plasmid DNA Manufacturing, Antibody Fragment Manufacturing, and Development of Analytical Tools. Its focus areas include Biopharma Outsourcing, CDMO and Biologics.
Company details
Xpress biologics is a contract research organisation offering services in the following areas designing of protein purification system (bacteria and yeasts), process development and manufacturing of new biologics (recombinant proteins, antibody fragments, and plasmid DNA), biosimilars and biobetters, and the management of the pre-clinical and clinical trials management of the GMP manufacturing. The company provides these services to human and veterinary healthcare markets and diagnostic markets. Additionally, the company also provides services in analytical testing.
- Headquarters Liege, Belgium
- Employees 51
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website xpress-biologics.com/en
- Social LinkedIn
- Acquired by Polyplus Transfection (Dec 2022)
- Legal Name Xpress Biologics
- Net Profit-$916.94 K (USD)-1557as on Dec 31, 2022
- EBITDA-$92.07 K (USD)-115as on Dec 31, 2022
- InvestorsPolyplus Transfection
& 1 more
- Employee Count51
- Acquired by
Products & Services of Xpress Biologics
Xpress Biologics offers a comprehensive portfolio of products and services, including Recombinant Protein Manufacturing, Plasmid DNA Manufacturing, Antibody Fragment Manufacturing, and Development of Analytical Tools.
Develops and produces recombinant proteins for research and clinical use.
Produces plasmid DNA for vaccine and therapeutic applications.
Manufactures antibody fragments for diagnostics and treatments.
Creates tools for quality control in biologics production.
Investors in Xpress Biologics
Xpress Biologics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Polyplus Transfection and ARCHIMED.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare industries are funded and supported globally by ARCHIMED. | archimed.group | Lyon, France | ||
Transfection Solutions for Healthcare and Life Sciences organizations | 2001 | polyplus-transfection.com | Illkirch Graffenstaden, France |
Investor details for Xpress Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Xpress Biologics
3 dated milestones of Xpress Biologics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Xpress Biologics is founded.
- Exit Acquired by ARCHIMED.
- Exit Acquired by Polyplus Transfection.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xpress Biologics
Complete news archive for Xpress Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xpress Biologics
Xpress Biologics was founded in 2014.
Xpress Biologics is headquartered in Liege, Belgium. It is registered at Liege, Liege, Belgium.
Xpress Biologics has 51 employees.
Xpress biologics is a contract research organisation offering services in the following areas designing of protein purification system (bacteria and yeasts), process development and manufacturing of new biologics (recombinant proteins, antibody fragments, and plasmid DNA), biosimilars and biobetters, and the management of the pre-clinical and clinical trials management of the GMP manufacturing. The company provides these services to human and veterinary healthcare markets and diagnostic markets. Additionally, the company also provides services in analytical testing.
Xpress Biologics offers Recombinant Protein Manufacturing, Plasmid DNA Manufacturing, Antibody Fragment Manufacturing, and Development of Analytical Tools.
Xpress Biologics has 2 investors. Key investors include Polyplus Transfection, and ARCHIMED.
Xpress Biologics operates through Xpress Biologics.
Yes. Xpress Biologics was acquired by Polyplus Transfection in December 2022.

